A progressive discovery strategy for anti-Alzheimer's drug identification:In vitro screening with an LPS-induced neuroinflammatory cell model and in vivo validation in 5xFAD mice
摘要
Background:Alzheimer's disease(AD)is the most prevalent neurodegenerative disorder.Cellular drug screening represents a key approach in the preclinical discovery of AD therapeutics.Moreover,selecting an appropriate cellular model is essential for exploring the mechanisms underlying AD pathogenesis.
Objective:This study aimed to establish a progressive strategy integrating cell model construction,monomer evaluation,and effec-tive component group-based drug discovery for the development of novel therapeutics targeting AD.
Methods:A novel AD12 cell line stably expressing the double-transgenic genes amyloid precursor protein(APP)695/presenilin 1(PS1)-ΔE9 was first constructed and subjected to lipopolysaccharide(LPS)stimulation.The resulting LPS-induced neuroinflamma-tory response was characterized using metabolomic analysis.Subsequently,16 alkaloids derived from traditional Chinese medicine(TCM)were screened with the LPS-AD12 cell model.Molecular docking was then performed to assess the binding affinity of ben-zoylaconitine(BAC)with APP and PS1 proteins.A targeted metabolomics approach focusing on amino acids and the tricarboxylic acid(TCA)cycle was applied to BAC-treated LPS-AD12 cells.Finally,aconite extract was administered to five-familial-AD-mutations(5xFAD)transgenic mice,and therapeutic efficacy was evaluated through phenotypic and metabolomic analyses.
Results:LPS stimulation induced neuroinflammation in AD12 cells,characterized by elevated levels of interleukin-6,amyloid-β1-42(Aβ1-42),and PS1.The primary metabolic pathways affected in AD12 cells included alanine,aspartate,and glutamate metabolism,as well as arginine biosynthesis.Notably,BAC significantly reduced the levels of Aβ1-42 and interleukin-6 in LPS-AD12 cells.Furthermore,molecular docking analyses revealed a strong binding affinity of BAC with APP and PS1 proteins.Targeted metabolomics analysis indicated that the pharmacological activity of BAC was primarily associated with its anti-inflammatory effects,modulation of the cholinergic signaling pathway,and regulation of energy metabolism.Behavioral experiments in 5xFAD mice,together with immuno-fluorescence assessments of brain tissues(amyloid-β,glial fibrillary acidic protein,and ionized calcium-binding adapter molecule 1),demonstrated that aconite extract treatment significantly alleviated AD-related symptoms.In addition,metabolomics-based mecha-nistic analyses revealed that serine,acetylcholine,ornithine,and gamma-aminobutyric acid exhibited consistent trends in both brain tissue and serum samples from treated mice.
Conclusion:This study established a novel AD12 cell model and an effective,reliable LPS-induced cell-based screening system.Additionally,we proposed a new drug discovery strategy integrating cell model construction,monomer evaluation,and effective component group-based drug discovery.This screening system has the potential to accelerate the identification of anti-AD agents and provides a feasible framework for subsequent in-depth investigations into new drug development from TCM,thereby contribut-ing to the modernization of TCM-derived therapeutics.